Skip to main content
EDIT
NASDAQ Life Sciences

Editas Medicine Reports Strong Preclinical Data for EDIT-401 in Hyperlipidemia

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.93
Mkt Cap
$283.928M
52W Low
$1.345
52W High
$4.537
52W Position info
118% above low
Off High info
35% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

EDIT has more than doubled off its 52-week low of $1.345.

Summary

Editas Medicine announced new preclinical data for its gene-editing candidate, EDIT-401, demonstrating significant and durable LDL-C reduction in non-human primates, supporting its advancement towards human clinical trials.


Key Events · Product Development and Regulatory · EDIT

  • Strong Preclinical Efficacy

    EDIT-401 achieved ≥90% mean LDL cholesterol (LDL-C) reduction across all dose groups in non-human primates with a single dose.

  • Durable Response Demonstrated

    LDL-C lowering was rapid and remained durable for approximately six months across evaluated dose levels.

  • Promising Preclinical Safety Profile

    Studies showed no adverse clinical observations at therapeutically relevant doses and high delivery to target hepatocytes with undetectable oocyte delivery.

  • Advancing Towards Clinical Development

    The data strengthens confidence in EDIT-401's potential as a one-time treatment for hyperlipidemia, supporting its continued advancement toward first-in-human clinical development.


Analysis · EDIT · Life Sciences

This filing details promising preclinical results for EDIT-401, a lead gene-editing candidate for hyperlipidemia. Achieving over 90% LDL-C reduction with durability in non-human primates is a strong indicator of therapeutic potential. For a gene-editing company like Editas, which has recently undergone restructuring, positive pipeline progress is crucial for investor confidence and future development funding. The data supports moving towards first-in-human clinical trials, a key milestone for biotech valuation.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EDIT was trading at $2.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.9M. The 52-week trading range was $1.35 to $4.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EDIT - Latest Insights

EDIT
Nov 09, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.75
Real-time Price: $2.47 info
Change: -$0.285 (-10%) info
Market Cap: $380.448M info
EDIT
Nov 09, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.61
Real-time Price: $2.47 info
Change: -$0.145 (-6%) info
Market Cap: $380.448M info
EDIT
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.61
Real-time Price: $2.47 info
Change: -$0.145 (-6%) info
Market Cap: $380.448M info
EDIT
Oct 08, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $2.47 info
Change: -$0.335 (-12%) info
Market Cap: $380.448M info
EDIT
Oct 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.73
Real-time Price: $2.47 info
Change: -$0.265 (-10%) info
Market Cap: $380.448M info